Though progress has been made in addressing the primary defects in dystrophin via exon skipping or gene-replacement therapies [2], means of mitigating the effects of eccentric injuries to the muscle of DMD patients have primarily been limited to treatment with palliative anti-inflammatory drugs. Here, DMD is linked to Duchenne muscular dystrophy.